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A B S T R A C T
Conventional immediate release dosage forms involve compressing the powder with a disintegrating agent that
enables rapid disintegration and dissolution upon oral ingestion. Among 3D printing technologies, the fused
deposition modelling (FDM) 3D printing technique has considerable potential for patient-speciTc dosage form.
However, the use of FDM 3D printing in tablet manufacturing requires large portion of polymer, which slows
down drug release through erosion and diffusion mechanisms. In this study, we demonstrate for the Trst time
the use of a novel design approach of caplets with perforating channels to accelerate drug release from 3D
printed tablets. This strategy has been implemented using a caplet design with perforating channels of increas-
ing width (0.2, 0.4, 0.6, 0.8 or 1.0 mm) and variable length, and alignment (parallel or at right angle to tablet
long axis). Hydrochlorothiazide (BCS class IV drug) was chosen as model drug as enhanced dissolution rate is
vital to guarantee oral bioavailability. The inclusion of channels exhibited an increase in the surface are/volume
ratio, however, the release pattern was also inUuenced by the width and the length of the channel. A channel
width 0.6 mm deemed critical to meet the USP criteria of immediate release products. Shorter multiple chan-
nels (8.6 mm) were more efTcient at accelerating drug release than longer channels (18.2 mm) despite having
comparable surface area/mass ratio. This behaviour may be linked to the reduced Uow resistance within the
channels and the faster fragmentation during dissolution of these tablets. In conclusion, the width and length of
the channel should be carefully considered in addition to surface area/mass when optimizing drug release from
3D printed designs. The incorporation of short channels can be adopted in the designs of dosage forms, implants
or stents to enhance the release rate of eluting drug from rich polymeric structures.
1. Introduction
Immediate release tablets is the most commonly used dosage form
[1,2]. This trend is likely to continue in oral drug delivery. Between
2005 and 2015, 79% of new drug approvals (NDAs) for oral products
were for immediate release formulations [3]. In fact, accelerating drug
release from tablet has been highly desirable in oral formulations for the
last few decades. Several advancements were introduced to accelerate
tablet disintegration and dissolution such as super-disintegrants [4 6],
effervescent [7 9] and alkaline solubiliser [10].
The Trst patent for compressed tablets was Tled in 1843 in England
in an effort to form a pill without using a large amount of binder that
slows drug release [11]. The compressing powder under high pressure
has since become the standard method for tablet manufacturing. The
formulation design of tablets has been well-established for decades us-
ing common ingredients such as Tller, binder, a gliding and disintegrant
as well as a material that allow fast disintegration in the gastric envi-
ronment. Later, between 1930s 1950s, in order to improve palatability,
ecstatic quality and patient compliance, Tlm coatings were introduced
[12].
The principal mechanism of tablet formation remained the same un-
til the introduction of powder based 3D printing technology, where
the use of powder bed allows the binding of powders in situ to form
tablets [13]. However, this has been at the expense of the ecstatic and
mechanical properties of these tablets, with poor Tnishing, rough sur-
face [14] and high friability value [15,16]. Recently, fused deposition
modelling (FDM) 3D printing has been proposed as an alternative 3D
printing technology for on demand fabrication of individualised dosage
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forms [17,18] and offered several advantages. It is a low cost produc-
tion unit with minimal space requirements and produces mechanically
resistant tablets without the need to a Tnishing step [17 20].
Unlike conventionally compressed tablets, where dissolution is Trst
initiated by tablet disintegration after water imbibition and particle
swelling, the disintegration and dissolution of FDM 3D printed tablets
may be dominated by erosion and diffusion mechanisms [17,18]. This
is resulted by the use of a high percentage of polymer for Tlament pro-
duction in hot melt extrusion HME (minimum polymer loading of 45%
w/w) [21]. Such polymer-rich structure has a significant effect on slow-
ing drug release from the fabricated tablets. This might be reUected in
numerous examples for extended drug release [18,22 27]. It is the im-
mediate release that is the most challenging to achieve from FDM 3D
printed structures [28,29].
Previous attempts investigated the effect of the external shape and
volume/mass ratio of 3D printed tablets on the pattern of extended
drug release [30]. Some efforts also exploited the inTll function of FDM
[17,31], and inkjet [31] 3D printers to modify drug release. However,
this approach was originally introduced to 3D printing to enhance the
structural integrity of the printed object while minimizing the use of ma-
terial. It necessitated the dissolution of the shells before media penetra-
tion and often yielded low-density Uoating tablets. In order to accelerate
drug release from FDM 3D printed structures, an alternative solution for
tablet disintegration and dissolution is essential.
In this research, we have introduced a novel tablet design with
built-in channels to accelerate drug release from 3D printed polymetha-
cylate tablets. The impact of channel width, length and position on in
vitro drug release has been investigated in addition to surface area/
volume ratio. This work also uniquely investigated the impact of such
design on changes in 3D printing objects throughout the dissolution
process and compared this solution to the traditional conventional ap-
proach of adding disintegrant. Hydrochlorothiazide, a biopharmaceuti-
cal classiTcation system (BCS) class IV drug with poor solubility and
permeability [32 34], was chosen as model drug as accelerating drug
release is essential to maintain oral bioavailability.
2. Materials and methods
2.1. Materials
Hydrochlorothiazide (HCT) (Tm = 268 C), triethyl citrate (TEC)
and tri-Calcium phosphate (TCP) were supplied by Sigma-Aldrich (UK).
Eudragit E was donated by Evonik Industries (Darmstadt, Germany).
Croscarmellose sodium (Ac-Di-Sol and Primellose ) was supplied by
FMC Biopolymer (USA) and DFE Pharma (Germany) respectively,
sodium starch glycolate (Primojel and Explotab ) were donated by
DFE Pharma (Germany) and JRS pharma LP (USA) respectively,
crosslinked polyvinylpyrrolidone (Polyplasdone-XL ) was donated by
Ashland (USA). Scotch Blue Painter's tape 50 mm was supplied by 3 M
(Bracknell, UK). All other agents were provided by Sigma Aldrich (UK).
2.2. Preparation and optimisation of <laments
An optimised ratio of Eudragit E: TEC: TCP: HCT
(46.75:3.25:37.5:12.5%wt) was employed to produce drug loaded Tla-
ments [29]. Approximately 10 g of materials was accurately weighed
and added gradually to counter Uow twin-screw hot melt extruder,
HAAKE MiniCTW (Karlsruhe, Germany). To allow homogeneous distri-
bution of the powders, the molten mass was mixed in the extruder for at
least 5 min prior to extrusion. The speciTc temperatures of initial feed-
ing and extrusion for the Tlament were 100 and 90 C respectively. A
torque control of 0.8 Nm was used to extrude out the Tlaments. Fila
ments were stored in sealed plastic bags at room temperature before 3D
printing.
For disintegrant containing Tlament, a ratio of Eudragit E: TEC: TCP:
disintegrant: HCT 46.75:3.25:33.5:4:12.5 were used to produce individ-
ual Tlaments for each of the following disintegrants: Ac-Di-Sol , Primel-
lose , Primojel , Polyplasdone-XL or Explotab .
2.3. Design and printing of tablets
The basic shape of the tablet is based on capsule-shaped tablet
(caplet) design at dimensions: 17.2 6.8 6.25 mm. In order to assess
the impact of tablet volume, a series of tablets of increasing tablet di-
mensions were designed and printed (Table 1). The caplet design (di-
mensions: 17.2 6.8 6.25 mm) was perforated with identical chan-
nels of square section and rectangular length. The widths of channel sec-
tion were 0.2, 0.4, 0.6, 0.8 or 1.0 mm. The impact of the length and
orientation of the channels within the caplet design was investigated by
applying either a) 9-long channel parallel to the long axis of the caplet
design or b) 18-shorter channels at right angle to the long axis of the
caplet design (Fig. 2). As it was not possible to include these channels
and maintain identical surface/volume ratio without fundamentally al-
tering tablet dimensions and shape, the dimensions of the channelled
tablet design were kept identical and the changes in surface area and
surface to volume ratio was reported in Table 2.
Tablets were constructed with the pre-prepared Tlaments using a
commercial FDM 3D printer with a 0.4 mm nozzle. The templates used
to print the tablets were designed in caplet shape using Autodesk 3ds
Max-Design 2016 software version 18.0 (Autodesk, Inc., USA). The de-
sign was saved in a stereolithography (.stl) Tle format and imported
to the 3D printer's software, MakerWare Version 2.4.0.17 (Makerbot
Industries, LLC. USA). Tablets were printed using modiTed settings of
the software for PLA Tlament as described in our previous work [21].
The temperature for 3D printing and build plate was 135 C and 60 C
respectively and at standard resolution. As the density of the printed
structure is dependant of the density of extruded Tlament and the voids
between the fused Tlaments layers (above and beyond the channels
space of the original design), it is important to maintain the same Tll-
ing pattern across the different designs. Therefore, the settings of the
slicing engine (inTll pattern = hexagonal, inTll density = 100%, layer
height = 200 m) were identical for all printed designs.
2.4. Thermal analysis
Samples (raw materials, extruded Tlaments and printed tablets)
were characterised using differential scanning calorimetry (DSC) and
thermogravimetric analysis (TGA). For DSC analysis, a differential scan-
ning calorimeter DSC Q2000 (TA Instruments, Elstree, Hertfordshire,
UK) with a heating rate of 10 C/min was used. Samples were Trst
cooled to − 50 C followed by an isotherm for 1 min and then heat scan
from − 50 to 300 C. Analysis was carried out under a nitrogen (50 mL/
min) purge. The data was analysed using TA 2000 analysis software.
Tzero TA aluminium pans and Tzero hermetic lids were used with an
approximate sample mass of 7 mg. All measurements were carried out
in triplicates.
For TGA analysis, raw materials, model drug, extruded Tlaments and
3D printed tablets were measured using a TGA Q500 (TA Instruments,
Elstree, Hertfordshire, UK). Samples (7 mg) were placed in 40 L alu-
minium pans and then heated from 25 to 500 C using a heating rate
of 10 C/min. The thermal decomposition (or degradation) proTle was
analysed using TA 2000 analysis software. The experiments were car-
ried out under nitrogen gas Uow of 50 mL/min. All measurements were
carried out in triplicates.
2
UN
CO
RR
EC
TE
D
PR
OO
F
M. Sadia et al. Journal of Controlled Release xxx (2017) xxx-xxx
Table 1
Measured dimensions, volumes, surface area, surface to volume and surface to mass ratios of CAD designs of solid tablets (no channels).
Tablet Dimensions
Volume
of CAD
design
(mm⁠3)
Mass of printed
caplets (mg)
Surface
area of
CAD
design
(mm⁠2)
Surface/
volume ratio
of CAD design
(mm⁠− 1)
CAD surface/
printed mass
(mm⁠2/mg)
X (mm) Y (mm) Z (mm)
Tablet-6 mm 6.22 0.1 2.16 0.06 2.08 0.06 23.57 30.84 4.16 46.05 2.0 1.49
Tablet-9 mm 8.72 0.26 3.36 0.13 3.14 0.09 79.54 110.93 4.43 103.62 1.3 0.93
Tablet-12 mm 11.42 0.06 4.61 0.5 4.84 0.16 188.66 211.8 0.71 184.21 1.0 0.87
Tablet-14 mm 13.88 0.2 6.07 0.04 5.27 0.11 299.43 405.53 16.21 250.74 0.8 0.62
Tablet-16 mm 16.02 0.38 6.98 0.13 6.15 0.1 446.97 535.35 4.29 327.5 0.73 0.61
Tablet-18 mm 17.29 0.34 6.85 0.06 6.09 0.05 636.4 785.73 1.44 414.49 0.65 0.53
Tablet Dimensions Volume
of CAD
design
(mm⁠3)
Mass of printed
caplets (mg)
Surface
area of
CAD
design
(mm⁠2)
Surface/
volume ratio
of CAD design
(mm⁠− 1)
CAD Surface/
printed mass
(mm⁠2/mg)
X (mm) Y (mm) Z (mm)
Tablet-6 mm 6.22 0.1 2.16 0.06 2.08 0.06 23.57 30.84 4.16 46.05 2.0 1.49
Tablet-9 mm 8.72 0.26 3.36 0.13 3.14 0.09 79.54 110.93 4.43 103.62 1.3 0.93
Tablet-12 mm 11.42 0.06 4.61 0.5 4.84 0.16 188.66 211.8 0.71 184.21 1.0 0.87
Tablet-14 mm 13.88 0.2 6.07 0.04 5.27 0.11 299.43 405.53 16.21 250.74 0.8 0.62
Tablet-16 mm 16.02 0.38 6.98 0.13 6.15 0.1 446.97 535.35 4.29 327.5 0.73 0.61
Tablet-18 mm 17.29 0.34 6.85 0.06 6.09 0.05 636.4 785.73 1.44 414.49 0.65 0.53
2.5. X-ray powder di=ractometry (XPRD)
A powder X-ray diffractometer, D2 Phaser with Lynxeye (Bruker,
Germany) was used to assess the physical form of model drugs in Eu-
dragit E, TCP, Eudragit E:TEC Tlament, blank and drug-loaded Tla-
ments, and 3D printed tablets. Samples were scanned from 2Theta = 5
to 50 using 0.01 step width and a 1 s time count. The divergence slit
was 1 mm and the scatter slit 0.6 mm. The wavelength of the X-ray was
0.154 nm using Cu source and a voltage of 30 kV. Filament emission
was 10 mA using a scan type coupled with a two theta/theta scintilla-
tion counter over 30 min.
2.6. Scanning electron microscopy
The surface morphology of the Tlaments and the printed tablets was
assessed using a Quanta-200 SEM microscope at 20 kV. All samples for
SEM visualisation were placed on a metallic stub and gold plated using
a JFC-1200 Fine Coater (Jeol, Tokyo, Japan). Photographs of the tablets
were captured with a Canon EOS-1D Mark IV (Canon Ltd., Japan).
2.7. X-ray micro-computed tomography (X CT)
A SkyScan1172 high-resolution X-ray micro computed tomography
(X CT) scanner (Bruker-microCT, Belgium) was utilized to analyse the
internal structure of the channelled tablet.
2.8. Characterization of the tablets properties
In order to assess the impact of channelled design on the mechani-
cal properties of the tablets, 20 tablets were randomly selected, weighed
and placed in a friability Tester Erweka type TAR 10 (Erweka GmbH,
Heusenstamm, Germany) and the drum was then rotated at 25 rpm
for 4 min. The tablets were reweighed and the differences in weight
were calculated and displayed as a percentage of the original sample
weight. Drug contents in the samples were assessed using an Agilent
UV-HPLC 1260 series (Agilent Technologies, Inc., Germany) equipped
with Kinetex C18 column (100 2.1 mm, particle size 2.6 m) (Phe-
nomenex, Torrance, USA). The mobile phase was (acetonitrile: water ad-
justed pH 3 with orthophosphoric acid) at ratio 70:30 and a Uow rate of
0.5 mL/min. The injection volume was 20 L and stop time was 5 min
per sample. The wavelength was set to 230 nm at 37 C and retention
time of the drug was 2.75 min. The method showed linearity between
1 and 100 mg/L with R⁠2 = 0.996 and limits of detection and quantiTca-
tion of 0.1 and 2.5 mg/L respectively. The accuracy was 107.1% 5.1
and 97% 0.5 at concentrations: 12.5 and 37.5 mg/L respectively.
2.9. In vitro dissolution test of the tablets
Drug release studies carried out using a USP II Erweka DT600 dis-
solution tester (Erweka GmbH, Heusenstamm, Germany). Three tablets
were randomly selected and individually placed in the dissolution ves-
sels each containing 900 mL of 0.1 M HCl at 50 rpm and 37 0.5 C.
Aliquots (4 mL) were manually collected using 5 ml Leur-Lock syringes
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Table2
Measureddimensions,volumes,surfacearea,surfacetovolumeandsurfacetomassratiosofCAD
designsofsolidandchannelledtablets.
Tablet design
Dimensions
Channeldimensions in
CAD design (mm)
Volume of CAD
design (mm
⁠3)
Mass of printed
caplets (mg)
Surface area of
CAD design (mm
⁠2)
Surface/volume ratio of
CAD design (mm
⁠−
1)
CAD surface/printed
mass (mm
⁠2/mg)
X (mm)
Y (mm)
Z (mm)
Solid design (no
channels)
16.99
0.1
6.79
0.01
6.09
0.05
No channels
553.81
785.73
1.44
377.8
0.682
0.481
9 channels
(0.2mm)
17.07
0.12
6.51
0.06
5.9
0.02
0.2
0.2
548.02
593
7.90
493.34
0.9
0.832
9 channels
(0.4mm)
16.89
0.03
6.53
0.06
5.9
0.06
0.4
0.4
530.46
579.33
6.54
607.59
1.15
1.049
9 channels
(0.6mm)
16.86
0.06
6.7
0.07
6.07
0.35
0.6
0.6
501.38
591
5.72
718.64
1.43
1.216
9 channels
(0.8mm)
16.78
0.08
6.78
0.03
5.9
0.02
0.8
0.8
460.95
571.33
0.53
825.89
1.79
1.446
9 channels
(1mm)
16.78
0.14
6.63
0.11
6.0f0.09
1
1
408.25
546.67
4.89
934.75
2.29
1.710
18 channels
(0.2mm)
16.98
0.09
6.52
0.02
6.0
0.12
0.2
0.2
549.07
552
3.62
471.19
0.86
0.854
18 channels
(0.4mm)
16.97
0.02
6.66
0.01
5.9
0.04
0.4
0.4
534.81
639.33
1.54
561.53
1.05
0.878
18 channels
(0.6mm)
16.96
0.07
6.65
0.04
6.1
0.05
0.6
0.6
511.19
604
1.79
647.5
1.27
1.072
18 channels
(0.8mm)
16.89
0.08
6.6
0.08
6.2
0.02
0.8
0.8
478.44
547.33
2.77
728.17
1.52
1.330
18 channels
(1mm)
16.68
0.07
6.6
0.02
6.21
0.1
1
1
436.91
540.67
11.21
802.4
1.84
1.484
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at 0, 5, 10, 15, 20, 25, 30, 40, 50 and 60 min time intervals and Tltered
through a Millex-HA 0.45 m Tlter. Each aliquot withdrawn was re-
placed with 4 mL of 0.1 M HCl. The absorbance of hydrochlorothiazide
was Tnally measured using a Jenway UV spectrophotometer (Bibby Sci-
entiTc Ltd., UK) at ⁠max of 278 nm. All dissolution test were carried out
in triplicates. In order to assess the disintegration behaviour of the 3D
printed tablet during dissolution test, the dissolution test has been video
recorded using a Sony HXR-NX3 camera (Sony Electronics Inc., Japan)
with the macro option on. Wide-angle green laser probes were used to
illuminate the tablets during dissolution in a dark room. All dissolution
test were carried out under sink condition [35].
2.10. Statistical analysis
One-way ANOVA was employed using SPSS Software (22.0.0.2)
to analyse the differences in the percentages of drug release at
T = 30 min. Differences in results between p 0.05 were considered
significant, p of 0.05 was considered not significant.
3. Results and discussion
Thiazide diuretic methacrylate tablets were produced using FDM
3D printing using Eudragit E based Tlament as the feed ink. Thermal
analysis indicated that the Tlament is stable at the preparation temper-
ature (Fig. S1a) and Uexible with a Tg of 29.5 C (Fig. S1b). X-ray dif
fraction spectra (Fig. S1c) conTrmed that a portion of hydrochloroth-
iazide was crystalline with the appearance of peak at 2Theta = 19.15
and 28.7 [36].
The poly-methacrylate tablets with a solid design (no channels) and
increasing tablet volume were 3D printed. The USP dissolution result il-
lustrated that the drug release rate slowed down with increased volume
(Fig. 1a, Table 1). This may be due to the reduced surface/mass ratio
of the larger tablets. As drug release from polymeric matrix is mainly
governed by erosion and diffusion mechanism [37 39], a slower release
was expected due to the smaller surface area/mass ratio.
An established approach to accelerate drug release from tablet is
through the incorporation of a disintegrant. Different disintegrants were
added in the tablet formation; however, they seemed to add little to ac-
celerating drug release (Fig. 1b). With their porous structure, disinte-
grants function by increasing water uptake into the tablet and elevating
the internal pressure trough swelling [40,41]. The inability of the dis-
integrant to induce tablet disintegration and in turn to accelerate drug
release may be due to the relatively excessive percentage of the polymer
in the tablet matrix. During the thermal processing of HME, it is possible
that the liqueTed polymer has coated the disintegrant particles, sealed
their pores and restricted their swelling during dissolution test. Further
increase in disintegrant resulted in a difTcult-to-print Tlament and did
not favour dissolution (unpublished work).
A schematic diagram of design of 3D printed tablet with built-in
channels is shown in Fig. 2. Tablets were crafted in an easy-to-swallow
Fig. 1. Impact of caplet dimensions and inclusion of disintegrant on in vitro drug release from 3D printed tablets (solid design). a) In vitro release of hydrochlorothiazide from different
sizes of Eudragit E tablets, the percentages of drug release at T = 30 min were considered as functionality outcome, one way ANOVA, P < 0.05 (mean SD, n = 3), b) in vitro release of
hydrochlorothiazide from Eudragit E caplets with/without commercially available disintegrants (mean SD, n = 3).
Fig. 2. Schematic illustration concept of perforating square sectioned channels. The dissolution medium will perforate through the channels and accelerate tablet disintegration and dis-
solution. The perforating channels were a1) parallel to long axis (9 long channels) or b1) at right angle with the long axis with 3D max rendered images of frontal, side and top view of
channelled tablet designs.
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caplet design. In order to accelerate drug release, the design has been
perforated with square channels of increasing widths. Two orientations
of the channels were proposed either parallel to the caplet's long axis or
at right angle to the axis. In order to maintain a comparable surface/
volume ratios, a larger number of shorter channels were incorporated.
The images of rendered tablet designs and photos of actual tablet
with increasing built-in channels are shown in Fig. 3. The printed struc-
tures maintained their shape, form and structure. The tablet remained
mechanically resistant with a friability value of zero, hence indicating
that the inclusion of channels did not alter the product's suitably to han-
dle and swallow.
In order to gain a better understanding of the internal structure
of the tablets, X CT technique was employed (Figs. 4 5). For 1.2 mm
channelled tablet, it is evident that the channel height is made of
5 channels each is 200 m high. The upper surface of each channel
within the tablet showed some downward facing curvatures and bends
as opposed to the lowed surface. This deformation might be related to
the absence of the support for the weight of this area during the so-
lidiTcation of the fusing layers. Such a deformation is also noted when
18-short short channels were 3D printed.
The impact of design on in vitro drug release from the constructed
tablet showed slow release from block tablets (Fig. 6). When short
channels of 0.2 0.4 mm channel were used, a limited improvement of
dissolution rate was noticed. However, increasing the channel width
to 0.8 1.0 mm led to a significant increase in theophylline release at
T = 30 min, reaching 78.7%, 88.5% and 92.3% for 9-long channel de-
sign, and 85%, 93.4% and 93.4% for 18-short channelled design. It is
important to highlight that such an increase in percentage of drug re-
lease with channelled tablets was critical to meet pharmacopeial criteria
of immediate release tablets.
Fig. 3. Rendered images of tablet designs with decreasing channel size with a) 9-long channels b) 18-short channels, photographs of tablets with decreasing channel size c) 9 long channels
d) 18 short channels.
Fig. 4. Visualisation of X CT data of 9-long channel design with 1 mm channel. View of the internal structure of the internal surface of the channel from (a) bottom and (b) top, c) X-Y
section and d) Y-Z section of the long channels across the tablets.
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Fig. 5. Visualisation of X CT data of 18-short channel design with 1 mm channels. a) Side view of the tablet, b) view of the top, c) X-Y section and d) X-Z section of the channels across
the tablets.
Fig. 6. Impact on channel width and orientation on dissolution release pattern from hydrochlorothiazide methacrylate tablet in USP II dissolution test in gastric medium (0.1 M HCl
pH 1.2, 50 rpm. Average SD) a) 18 long tablets, and b) short tablets.
Several literature reports directly linked the increase in dissolution
rate to an increase in the total surface area in multi-units [42 44] and
3D printed tablets [30]. It was expected that in vitro hydrochloroth-
iazide release was directly related to surface area/volume. However,
the length of the channel appeared to have a significant effect on the
extent of drug release. For instance, the use of 18-short channels has
been more effective in increasing in vitro drug release at T = 30 min
compared to the 9-long channel design despite having significantly
lower surface/volume ratio (Table 2). Wide-angle green light imaging
of the Trst 10 min of the dissolution test conTrms the surface erosion
of 3D printed tablet during dissolution test in both channel designs
(Fig. 7). The imaging conTrmed a faster erosion from 18-short chan-
nels design in comparison to 9-channels (44.3% versus 38.3% after
T = 10 min) (p < 0.05).
Previous attempts to modify the internal structure of 3D printed
tablets by modifying the inTll percentage [17,22,45]. This led to forma-
tion of a low density and Uoating tablets, where the penetration of aque-
ous medium takes place in a chamber by chamber order. In contrast, the
proposed channelled approach allowed the tablet to be immerged in the
medium while preserving an easy-to-swallow structure.
The changes in the shape of the channelled tablets during dissolu-
tion process have also been monitored at 5 min intervals (Fig. 8). Both
tablet designs showed an expansion in the width of the channels during
7
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Fig. 7. Wide-angle green light imaging during the Trst 10 min of USP II dissolution test of 3D printed hydrochlorothiazide tablets with a) solid design, b) long 9 channel design and c) 18
short channel design using mono-colour laser light. (For interpretation of the references to colour in this Tgure legend, the reader is referred to the web version of this article.)
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Fig. 8. Impact of tablet design and channel length on the erosion pattern of 3D printed tablets. Photograph of 3D printed tablets before and after 5, 10, 15, 20, 25 and 30 min of under-
taking USP II dissolution test in gastric medium (pH 1.2) with a) solid design, b) long 9 channel design and c) 18 short channel designs.
the dissolution process with a progressing decrease in the thickness of
inter-channel walls. This has been accompanied by a loss in the square
shape of the channel section and the formation of more rounded sec-
tions. As the inner diameter of the channel increased, the inter-chan-
nel spaces became narrower leading to the fragmentation of the tablet
into smaller fractions in the dissolution medium. Such effect is more
pronounced in the designs of shorter channels, where inter-channel do-
mains are shorter (Fig. 8c).
An important factor that impact the pattern of drug release is the
Uow of gastric medium through the channels during the dissolution
process. The area within channel of L length and W width can be ex-
pressed as 4WL. If is viscosity of dissolution medium, the force needed
to drive the pressure force within the channel. The velocity gradient will
be expressed as and the pressure force applied to move the channel is
.
And the viscosity force will be - 4WL.
The longer the channel the higher the hydraulic forces needed to al-
low drug Uow.
However, the significant reduction in the length of the channel in
tablets with shorter channel reduces the friction surface area leading to
a faster Uow of the medium. It is also important to highlight that with
erosion of methacrylate matrix, the width of the channel, W will be in-
creased, leading to a reduction in the resistance to Uow and accelerating
the Uow rate, hence leading to a faster drug release. It is also worth not-
ing that channelling system is more suitable to non-swelling systems as
a swellable polymer matrix might lead to narrowing or closure of chan-
nels upon introduction to aqueous medium.
In summary, this work clearly demonstrated the potential of chan-
nelled system in modifying the release and fragmentation pattern of
FDM 3D printed tablets. With development of novel materials and sig-
nificant improvement in the resolution and accuracy of future 3D print-
ing technologies [46], we anticipate that CAD will allow production
of more detailed structures with different mechanical and drug release
functionality from established polymeric matrices.
4. Conclusions
We have presented an alternative novel design approach through
engineering perforating channels within the tablet design. This com-
plex structure design does not only increase the surface area of the
tablet, but also facilitate media perforation through the structure. A
channel size of 0.6 mm is essential to accelerate the drug release and
meet pharmacopeial criterion for immediate release products. The use
of large number of shorter channels proved more efTcient in accelerat
ing drug release from the tablet than longer channels. This has been at-
tributed to the reduced resistance to Uow and faster fragmentation of
the tablet of shorter channels during dissolution test. The incorporation
of short channels can be adopted in the designs of dosage forms, im-
plants or stents to enhance the release rate of eluting drug from rich
polymeric structures. It is anticipated that a new generation of dosage
form of complex geometry will emerge to tailor drug release via control-
ling the media Uow through these built-in channels.
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.jconrel.2017.11.022.
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